If You Invested $10,000 In AbbVie Stock 10 Years Ago, How Much Would You Have Now?

AbbVie Inc. ABBV discovers, develops, manufactures, and sells pharmaceuticals worldwide.

It is set to report its Q3 2024 earnings on Oct. 30, before the market opens. Wall Street analysts expect the company to post an EPS of $2.95 in the year-ago period. According to Benzinga Pro, quarterly revenue is expected to reach $14.26 billion, up from $13.93 billion in the previous year.

Check It Out:

• A billion-dollar investment strategy with minimums as low as $10 — you can become part of the next big real estate boom today.
  This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Flagship Fund before investing. This and other information can be found in the Fund's prospectus. Read them carefully before investing.
• These five entrepreneurs are worth $223 billion – they all believe in one platform that offers a 7-9% target yield with monthly dividends

If You Bought AbbVie Stock 10 Years Ago

The company's stock traded at approximately $59.52 per share 10 years ago. If you had invested $10,000, you could have bought roughly 168 shares. Currently, shares trade at $187.88, meaning your investment's value could have grown to $31,566 from stock price appreciation alone. However, AbbVie also paid dividends during these 10 years. 

AbbVie's dividend yield is currently 3.30%. Over the last 10 years, it has paid about $42.83 in dividends per share, which means you could have made $7,196 from dividends alone. 

Summing up $31,566 and $7,196, we end up with the final value of your investment, which is $38,762. This is how much you could have made if you had invested $10,000 in AbbVie stock 10 years ago. This means a total return of 287.62%. In comparison, S&P 500 total return for the same period is 238.56%.

Trending: If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it?

What Could The Next 10 Years Bring? 

AbbVie has a consensus rating of "Overweight" and a price target of $184 based on the ratings of 31 analysts. The price target implies a potential downside of around 2% from the current stock price.

On July 25, the company announced its Q2 2024 earnings, posting an adjusted EPS of $2.65, down 8.9% year-over-year, beating the consensus of $2.57, as reported by Benzinga.

Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. On an operational basis, sales were up 5.6%.

AbbVie raised its 2024 adjusted EPS guidance from $10.61-$10.81 to $10.71-$10.91 versus the consensus of $10.78. This guidance includes an unfavorable impact of $0.60/share related to acquired IPR&D and milestones expense.

Check out this article by Benzinga for AbbVie’s recent short interest.

Given no expected upside potential, growth-focused investors may not find AbbVie stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 3.30%.

You Can Profit From Real Estate Without Being A Landlord

Real estate is a great way to diversify your portfolio and earn high returns, but it can also be a big hassle. Luckily, there are other ways to tap into the power of real estate without owning property.

The Arrived Homes investment platform has created an Income Fund, which provides access to a pool of short-term loans backed by residential real estate with a target 7% to 9% net annual yield paid to investors monthly. The best part? Unlike other private credit funds, this one has a minimum investment of only $100. 

Looking for fractional real estate investment opportunities? The Benzinga Real Estate Screener features the latest offerings.

Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset’s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.